Oxford, UK: 17 May 2007: Oxford BioMedica (LSE: OXB), the leading gene therapy company, today announces that scientists from its wholly owned subsidiary, Oxxon Therapeutics, and its clinical collaborators will present results from a Phase II trial of Hi-8 MEL in melanoma at the American Association of Immunologists (AAI) Annual Meeting, to be held on 18-22 May in Miami, Florida. The abstract has been selected for both an oral and a poster presentation.
